布罗莫克里因通过中央多巴胺D2受体独立机制改善肥胖小鼠的葡萄糖耐受性
Hiroshi Tsuneki1,2, Takahiro Maeda1, Mayumi Takatsuki1
1Department of Clinical Pharmacology, University of Toyama, Toyama, Japan.
PloS one
|March 26, 2025
概括
布罗莫克里因通过减少肝脏内质网膜应激来改善葡萄糖耐受性,而不是通过多巴胺D2受体. 这项研究揭示了其在肥胖中抗糖尿病作用的外围机制.
科学领域:
- 内分泌学和新陈代谢学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 作为多巴胺D2受体激活剂的布罗莫克里普丁用于治疗2型糖尿病,但其抗糖尿病机制尚不清楚.
- 了解烯的作用对于优化其在代谢障碍中的治疗用途至关重要.
研究的目的:
- 调查布罗莫克里因改善2型糖尿病中葡萄糖代谢的机制.
- 为了确定多巴胺受体和外围影响在布罗莫克里普丁抗糖尿病作用中的作用.
主要方法:
- 在小鼠 (野生型,多巴胺D2,D1和素缺乏) 中进行药理和遗传淘汰实验.
- 评估葡萄糖新陈代谢,血糖水平,以及肝脏内 плазма网膜 (ER) 压力标志物.
- 使用人类肝瘤 HepG2 细胞进行体外研究,以检查 ER 应激反应.
主要成果:
- 布罗莫克里普丁改善了饮食诱导的肥胖和遗传肥胖小鼠的葡萄糖耐受性,独立于多巴胺D2受体缺乏.
- 该药物降低了肝脏ER压力标志物,表明它在肝脏平衡中起作用.
- 低度的布罗姆克里普丁可以保护HepG2细胞免受ER压力,这表明它具有预先条件的作用.
结论:
- 布罗莫克里普丁的抗糖尿病作用是由外周机制调解的,特别是通过促进肝脏ER恒温.
- 中央多巴胺D2受体通路不是烯对葡萄糖代谢的有益影响的主要媒介.
- 勃罗莫克里因可能通过ER在肝脏中的压力预调而产生治疗效益.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
144
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
144
01:24Glucagon-like Receptor Agonists
277
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
277
01:16Hormones Regulating Blood Glucose
2.9K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
2.9K
01:23Dipeptidyl Peptidase 4 Inhibitors
146
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
146
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
226
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
226
01:06Oral Hypoglycemic Agents: Glinides
116
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
116